search
Back to results

Evaluation of PillCam® Express Capsule Endoscopy Delivery System (RD-300)

Primary Purpose

Small Bowel Disease, Inflammatory Bowel Disease

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PillCam® Express Capsule Endoscopy Delivery System
Sponsored by
Medtronic - MITG
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Small Bowel Disease focused on measuring capsule endoscopy, small bowel disease, inflammatory bowel disease, Subjects indicated for EGD endoscopy

Eligibility Criteria

2 Years - 85 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 2 years
  • Subject scheduled for EGD endoscopy with a 2.8 mm (or greater) working channel

Exclusion criteria:

  • Subject is known or is suspected to suffer from bowel obstruction or bowel perforation at the time of presentation
  • Subject has history of UGI tract surgery (e.g., Billroth I, Billroth II, esophagectomy, gastrectomy, bariatric procedure)
  • Presence of an electro-medical device (pacemaker or internal cardiac defibrillator)
  • Subject is pregnant
  • Subject is expected to undergo a MRI examination within 7 days after ingestion of the capsule
  • Subject has known allergy to conscious sedation medications
  • Subject or legal guardian is not able to provide written informed consent

Sites / Locations

  • Alabama Digestive Disorders Center, P. C.
  • Alabama Liver and Digestive Specialists
  • RANY -Research Associates of New York (NY Gastroenterology Associates)

Outcomes

Primary Outcome Measures

Number of Participants With Successful Capsule Placement Into the Duodenum Using Capsule Delivery System
The number of capsules that successfully were in the duodenum as indicated by video images

Secondary Outcome Measures

Physician's Subjective Assessment of the Ease of Capsule Placement
The physician was required to assess the ease of use while answering a designated questionnaire. In addition, qualitative analysis was reformed with regard to all the open questions.

Full Information

First Posted
March 15, 2010
Last Updated
September 30, 2020
Sponsor
Medtronic - MITG
search

1. Study Identification

Unique Protocol Identification Number
NCT01088646
Brief Title
Evaluation of PillCam® Express Capsule Endoscopy Delivery System
Acronym
RD-300
Official Title
Evaluation of PillCam® Express Capsule Endoscopy Delivery System
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
May 2010 (Actual)
Study Completion Date
May 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic - MITG

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and efficacy of a trans-endoscopic capsule placement Capsule Endoscopy Delivery System.
Detailed Description
Natural ingestion of a wireless capsule endoscope (e.g. PillCam™ SB) is contraindicated in subjects with oropharyngeal or mechanical dysphagia, gastroparesis and known or suspected anatomical abnormalities. In addition, ingestion of a wireless capsule endoscope may be challenging in the pediatric population. The PillCam® Express Capsule Endoscopy Delivery System is intended to provide physicians with the capability to place capsules in the proximal duodenum using the accessory channel of a standard endoscope. The PillCam™ SB capsule to be used in this study was cleared by the FDA in August 2001 for small bowel evaluation. It has been ingested to date by more than 1,000,000 people worldwide and is well accepted by subjects and physicians as well as the professional societies. Further details of the PillCam®Express Capsule Endoscopy Delivery System can be found in the device description section. This study is designed to evaluate the performance and safety of the Capsule Endoscopy Delivery System in subjects indicated to undergo a standard Esophagogastroduodenoscopy (EGD) endoscopy

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Small Bowel Disease, Inflammatory Bowel Disease
Keywords
capsule endoscopy, small bowel disease, inflammatory bowel disease, Subjects indicated for EGD endoscopy

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
To evaluate the safety and efficacy of an endoscopic capsule placement device.
Masking
Investigator
Allocation
N/A
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
PillCam® Express Capsule Endoscopy Delivery System
Intervention Description
The PillCam® Express Capsule Endoscopy Delivery System is comprised of three parts: a catheter, a syringe and the capsule holder. The catheter is passed through the accessory channel of a standard endoscope and the capsule holder is snapped on to the distal end of the device. The endoscope is used to guide the Capsule Endoscopy Delivery System to the proximal duodenum. The capsule is then released pneumatically, using an air-filled syringe attached to the proximal end of the catheter. Once the capsule is deployed, the endoscope is withdrawn and the capsule holder is cut off at the distal part of the device with scissors. The catheter is then retracted and discarded. The PillCam® Express Capsule Endoscopy Delivery System is single-use, disposable and latex-free.
Primary Outcome Measure Information:
Title
Number of Participants With Successful Capsule Placement Into the Duodenum Using Capsule Delivery System
Description
The number of capsules that successfully were in the duodenum as indicated by video images
Time Frame
up to 7 days
Secondary Outcome Measure Information:
Title
Physician's Subjective Assessment of the Ease of Capsule Placement
Description
The physician was required to assess the ease of use while answering a designated questionnaire. In addition, qualitative analysis was reformed with regard to all the open questions.
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 2 years Subject scheduled for EGD endoscopy with a 2.8 mm (or greater) working channel Exclusion criteria: Subject is known or is suspected to suffer from bowel obstruction or bowel perforation at the time of presentation Subject has history of UGI tract surgery (e.g., Billroth I, Billroth II, esophagectomy, gastrectomy, bariatric procedure) Presence of an electro-medical device (pacemaker or internal cardiac defibrillator) Subject is pregnant Subject is expected to undergo a MRI examination within 7 days after ingestion of the capsule Subject has known allergy to conscious sedation medications Subject or legal guardian is not able to provide written informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jonathan Leighton, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Peter Legnani, MD
Organizational Affiliation
Private Practice New York, New York
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alabama Digestive Disorders Center, P. C.
City
Huntsville
State/Province
Alabama
ZIP/Postal Code
35802
Country
United States
Facility Name
Alabama Liver and Digestive Specialists
City
Montgomery
State/Province
Alabama
ZIP/Postal Code
36116
Country
United States
Facility Name
RANY -Research Associates of New York (NY Gastroenterology Associates)
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Evaluation of PillCam® Express Capsule Endoscopy Delivery System

We'll reach out to this number within 24 hrs